ea0070aep923 | Thyroid | ECE2020
Krajewska Jolanta
, Kukulska Aleksandra
, Paliczka-Cieslik Ewa
, Gawlik Tomasz
, Olczyk Tomasz
, Ledwon Aleksandra
, Michalik Barbara
, Kropinska Aleksadra
, Handkiewicz-Junak Daria
, Jarzab Barbara
Introduction: To date, only four tyrosine kinase inhibitors (TKIs) have demonstrated beneficial effect on progression free survival in advanced medullary thyroid cancer (MTC; vandetanib and cabozantinib) andradioiodine-refractory differentiated thyroid cancer (RR-DTC; sorafenib and lenvatinib). However, there is still lack of unequivocal proofs of their significant impact on overall survival. Therefore, treatment-related side effects and their potential impact on quality of li...